An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs AVB 620 (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Avelas BioSciences
- 03 Aug 2017 According to an Avelas Biosciences media release, the first patient has been dosed in this study.
- 10 Jul 2017 Status changed from not yet recruiting to recruiting.
- 10 Apr 2017 Status changed from planning to not yet recruiting.